The Antiinflammatory Cytokine Interleukin-13 is not Detectable in the Circulation of Multiple Sclerosis Patients and is not Inducible by Interferon-β 1b Treatment, that Neither Modifies its ex vivo Secretion from Peripheral Blood Mononuclear Cells

References

• Olsson T. Critical influences of the cytokine orchestration on the outcome of myelin-antigen specific T cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev. 1995; 144: 245–268
   PubMed Web of Science ®Google Scholar
• Liblau R. S., Singer M S, McDevitt H. O. Th and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 1995; 16: 34–38
   PubMedGoogle Scholar
• Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diab. Metab. Rev. 1998; 14: 129–151
   PubMed Web of Science ®Google Scholar
• Bendtzen K. Cytokines and natural regulator of cytokines. Immunol. Letters 1994; 43: 111–123
   PubMed Web of Science ®Google Scholar
• Hafler D A, Weiner H L. Immunological mechanisms and therapy in multiple sclerosis. Immunol. Rev. 1995; 144: 75–107
   PubMed Web of Science ®Google Scholar
• Hunter S R, Rodriguze M. Multiple sclerosis: a unique immunopathological syndrome of the central nervous system. Springer Semin. Immunopathoi 1995; 17: 89–105
   PubMed Web of Science ®Google Scholar
• Nicoletti E, Patti F., Cocuzza C, Zaccone P., Nicoletti A., Di Marco R., Reggio A. Elevated serum levels of interleu-kin-12 in chronic progressive multiple sclerosis. J. Neuroim-munoi 1996; 70: 87–90
   PubMed Web of Science ®Google Scholar
• Comabella M., Balashov K., Issazadeh S., Smith D., Weiner H. L., Khoury S J. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J. Clin. Invest 1998; 102: 671–678
   PubMed Web of Science ®Google Scholar
• Rieckmann P., Albrecht M., Kitze B., et al. Tumor necrosis factor-α messanger RNA expression in patients with with relapsing remitting multiple sclerosis is associated with disease acitivity. Ann. Neurol 1995; 37: 82–88
   PubMed Web of Science ®Google Scholar
• Nicoletti E, Patti F., Di Marco R., Zaccone P., Nicoletti A., Meroni P. L., Reggio A. Circulating levels of IL-1 ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-β treatment. Cytokine 1996; 8: 395–400
   PubMed Web of Science ®Google Scholar
• Nicoletti E, Di Marco R., Patti E, Reggio E., Nicoletti A., Zaccone P, StivaJa E., Meroni P. L., Reggio A. Blood levels of transforming growth factor-beta 1 (TGF-Pl) are elevated in both relapsing remitting and chronic progressive multiple scelrosis (MS) patients and are further augmented by treatment with interferon-beta-1 b (IFN-β-lb). Clin. Exp. Immunol 1998; 113: 96–99
   PubMed Web of Science ®Google Scholar
• Hartung H P, Michels M., Reiners K., Seeldrayers P., Arche-Los J J., Toyka. Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology 1993; 43: 2331–2335
   PubMedGoogle Scholar
• Swanborg R H. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clin. Immunol. Immunopathoi 1995; 77: 4–13
   PubMedGoogle Scholar
• Arnason B GW. Interferon-beta in mutliple sclerosis. Clin. Immunol. Immunopathoi 1996; 81: 1–11
   PubMedGoogle Scholar
• de Vries J E. The role of IL-13 and its receptor in allergy and inflammatory responses. J. Allergy Clin. Immunol 1998; 102: 165–169
   PubMed Web of Science ®Google Scholar
• Poser C. M., Paty D. W., Scheinberg L., et al. New diagnostic criteria for mutliple sclerosis: guidelines for research protocols. Ann. Neurol 1983; 13: 227–231
   PubMed Web of Science ®Google Scholar
• Nicoletti E, Meroni P. L., Barcellini W., et al. Enhanced percentage of CD5+ B lymphocytes in newly diagnosed IDDM patients. Immunol. Letters 1990; 23: 211–215
   PubMed Web of Science ®Google Scholar
• Minty A., Asselin S., Bensussan A., Shire D., Vita N., Vyakarnam A., Wijdenes J., Ferrara P., Caput D. The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differentia] effects on T lymphocytes. Eur. Cyt. Network 1997; 8: 203–213
   PubMed Web of Science ®Google Scholar
• Lentsch A. B., Shanley T P, Sarma V., Ward P A. In vivo suppression of NF-KB and preservation of IKBo by interleu-kin-10 and interleukin-13. J. Clin. Invest 1997; 100: 2443–2448
   PubMed Web of Science ®Google Scholar
• Muchamuel T., Menon S., Pisacane P., Howard M C, Cockayne D A. IL-13 protects mice from lipopolysaccha-ride-induced lethal endotoxemia. Correlation with down-modulation of TNF-α, IFN-γ and IL-12 production. J. Immunol 1997; 158: 2898–2903
   PubMed Web of Science ®Google Scholar
• Nicoletti E, Mancuso G., Cusumano V., Di Marco R., Zaccone P., Bendtzen K., Teti G. Prevention of endot-oxin-induced lethality in neonatal mice by interleukin-13. Eur. J. Immunol 1997; 27: 1580–1583
   PubMed Web of Science ®Google Scholar
• Baumhofer J. M., Beinhauer B. G., Wang J. E., Brandmeier H., Geissler K., Losert U., Philip R., Aversa G., Rogy M A. Gene transfer with IL-4 and IL-13 improves survival in lethal endotoxemia in the mouse and ameliorates peritoneal macrophages immune competence. Eur. J. Immunol 1998; 28: 610–615
   PubMed Web of Science ®Google Scholar
• Bessis N., Boissier M C, Ferrara P., Blankenstein T., Fradel-Izi D., Foumier C. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur. J. Immunol 1996; 26: 2399–2403
   PubMed Web of Science ®Google Scholar
• Mulligan M. S., Warner R. L., Foreback J. L., Shanley T. P., Ward P A. Protective effects of IL-4, IL-10, IL-12 and IL-13 in IgG immune complex-induced lung injury. Role of endogenous IL-12. J Immunol 1997; 159: 3483–3489
   PubMed Web of Science ®Google Scholar
• Zaccone P., Phillips J., Conget I., Gomis R., Haskins K., Minty A., Bendtzen K., Cooke A., Nicoletti E. Interleukin-13 prevents autoimmune diabetes in NOD mice. Diabetes 1999; 48: 1522–1528
   PubMed Web of Science ®Google Scholar
• Cash E., Minty A., Ferrara P., Caput D., Fradelizi D., Rott O. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. J. Immunol 1994; 153: 4258–4267
   PubMed Web of Science ®Google Scholar
• Rudick A. R., Ransohoff R. M., Peppier R., Vandebrug Meden-Dorp S., Lehmann P., Alam J. Interferon-beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann. Neurol 1996; 40: 618–627
   PubMed Web of Science ®Google Scholar
• Byskosh P., Reder A T. Interferon beta-lb effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis. Mult. Scler 1996; 1: 262–269
   PubMedGoogle Scholar